Lung Cancer Clinical Trial
Real World Data on Gi(l)Otrif® Dose Adjustment
Summary
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.
Eligibility Criteria
Inclusion criteria:
Age = 18 years
Patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), tyrosine kinase inhibitors (TKI)-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
Signed and dated written informed consent per regulations. (Exemption of a written informed consent for retrospective observational studies in some countries per local regulations and legal requirements.)
Exclusion criteria:
Any contraindication to Gi(l)otrif® as specified in label.
Patients with uncommon mutations are excluded as uncommon mutations are not within label in all participating countries (e.g. USA).
Patients still on treatment with Gi(l)otrif® will be excluded unless treatment period is > or = 6 months.
Patients treated with Gi(l)otrif® within an interventional trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 29 Locations for this study
Bronx New York, 10461, United States
Charlotte North Carolina, 28201, United States
Wien , 1140, Austria
Vancouver British Columbia, V5Z 4, Canada
Besancon , 25030, France
Dijon Cedex , 21079, France
Paris , 75908, France
Paris , 75970, France
Essen , 45147, Germany
Nürnberg , 90419, Germany
Oldenburg , 26121, Germany
Alessandria , 15121, Italy
Lecce , 73100, Italy
Aichi, Nagoya , 464-8, Japan
Okayama, Kurashiki , 710-8, Japan
Daegu , 705-7, Korea, Republic of
Jeonju , 54907, Korea, Republic of
Pusan , 49241, Korea, Republic of
Ciudad De México , 01120, Mexico
Monterrey , 64060, Mexico
Zapopan , 45050, Mexico
Bydgoszcz , 85796, Poland
Cracow , 31331, Poland
Poznan , 60-56, Poland
Singapore , 11922, Singapore
Singapore , 16961, Singapore
Badalona (Barcelona) , 08916, Spain
Madrid , 28006, Spain
Taichung , 40447, Taiwan
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.